Cartesian Therapeutics Highlights Progress and 2024
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track...
Source: globenewswire.com
Nasdaq Selb News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq Selb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Selb Today - Breaking & Trending Today
Selecta Biosciences (NASDAQ:SELB) Research Coverage Started at StockNews.com
StockNews.com initiated coverage on shares of Selecta Biosciences (NASDAQ:SELB – Free Report) in a report published on Saturday morning. The brokerage issued a hold rating on the stock. Several other research firms have also recently weighed in on SELB. HC Wainwright reaffirmed a buy rating and set a $5.00 price objective on shares of Selecta […]
Source: etfdailynews.com
Selecta Biosciences, Inc. (NASDAQ:SELB) Receives $3.83 Average Target Price from Brokerages
Selecta Biosciences, Inc. (NASDAQ:SELB – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year […]
Source: tickerreport.com
Analysts Set Selecta Biosciences, Inc. (NASDAQ:SELB) Target Price at $3.83
Shares of Selecta Biosciences, Inc. (NASDAQ:SELB – Get Free Report) have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target […]
Source: wkrb13.com
Selecta Biosciences, Inc. (NASDAQ:SELB) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Selecta Biosciences, Inc. (NASDAQ:SELB – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year […]
Source: wkrb13.com